- Under Priority Review status, the FDA has accepted supplemental marketing applications from Bristol-Myers Squibb (NYSE:BMY) and Exelixis (NASDAQ:EXEL) seeking approval to use the combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) to treat advanced renal cell carcinoma (RCC).
- The agency's action date is February 20, 2021.
- https://seekingalpha.com/news/3623133-fda-oks-accelerated-review-for-opdivo-cabometyx-combo-for-kidney-cancer
Monday, October 19, 2020
FDA OKs accelerated review for Opdivo/Cabometyx combo for kidney cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.